Reported Earnings • May 16
First quarter 2026 earnings released: NT$0.63 loss per share (vs NT$0.64 loss in 1Q 2025) First quarter 2026 results: NT$0.63 loss per share. Net loss: NT$111.9m (loss widened 27% from 1Q 2025). Reported Earnings • Mar 27
Full year 2025 earnings released: NT$2.57 loss per share (vs NT$2.68 loss in FY 2024) Full year 2025 results: NT$2.57 loss per share. Net loss: NT$389.0m (loss widened 5.7% from FY 2024). New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.18b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Market cap is less than US$100m (NT$3.18b market cap, or US$99.2m). Ankündigung • Mar 06
Intech Biopharm Corporation, Annual General Meeting, May 27, 2026 Intech Biopharm Corporation, Annual General Meeting, May 27, 2026. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan New Risk • Jan 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Reported Earnings • Nov 12
Third quarter 2025 earnings released: NT$0.88 loss per share (vs NT$0.70 loss in 3Q 2024) Third quarter 2025 results: NT$0.88 loss per share (further deteriorated from NT$0.70 loss in 3Q 2024). Net loss: NT$144.1m (loss widened 50% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. New Risk • Nov 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$371m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$371m free cash flow). Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.7m). Market cap is less than US$100m (NT$2.51b market cap, or US$80.8m). New Risk • Sep 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$2.93b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.8m). Market cap is less than US$100m (NT$2.93b market cap, or US$96.6m). Reported Earnings • Aug 11
Second quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.68 loss in 2Q 2024) Second quarter 2025 results: NT$0.23 loss per share (improved from NT$0.68 loss in 2Q 2024). Net loss: NT$33.2m (loss narrowed 64% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Jun 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m). New Risk • Jun 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m). Reported Earnings • May 14
First quarter 2025 earnings released: NT$0.64 loss per share (vs NT$0.55 loss in 1Q 2024) First quarter 2025 results: NT$0.64 loss per share (further deteriorated from NT$0.55 loss in 1Q 2024). Net loss: NT$88.4m (loss widened 18% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year. Ankündigung • Apr 29
Intech Biopharm Corporation to Report Q1, 2025 Results on May 06, 2025 Intech Biopharm Corporation announced that they will report Q1, 2025 results on May 06, 2025 Reported Earnings • Mar 18
Full year 2024 earnings released: NT$2.68 loss per share (vs NT$2.81 loss in FY 2023) Full year 2024 results: NT$2.68 loss per share. Net loss: NT$368.2m (loss widened 8.9% from FY 2023). New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.30b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$34m revenue, or US$1.0m). Market cap is less than US$100m (NT$3.30b market cap, or US$100.0m). Ankündigung • Feb 25
Intech Biopharm Corporation to Report Fiscal Year 2024 Results on Mar 04, 2025 Intech Biopharm Corporation announced that they will report fiscal year 2024 results on Mar 04, 2025 Reported Earnings • Nov 18
Third quarter 2024 earnings released: NT$0.70 loss per share (vs NT$0.73 loss in 3Q 2023) Third quarter 2024 results: NT$0.70 loss per share. Net loss: NT$96.0m (loss widened 12% from 3Q 2023). New Risk • Oct 05
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: NT$32m (US$999k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.2% per year over the past 5 years. Revenue is less than US$1m (NT$32m revenue, or US$999k). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Reported Earnings • Aug 18
Second quarter 2024 earnings released: NT$0.68 loss per share (vs NT$0.62 loss in 2Q 2023) Second quarter 2024 results: NT$0.68 loss per share (further deteriorated from NT$0.62 loss in 2Q 2023). Net loss: NT$92.6m (loss widened 27% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Aug 02
Intech Biopharm Corporation to Report Q2, 2024 Results on Aug 09, 2024 Intech Biopharm Corporation announced that they will report Q2, 2024 results on Aug 09, 2024 Ankündigung • Apr 28
Intech Biopharm Corporation to Report Q1, 2024 Results on May 03, 2024 Intech Biopharm Corporation announced that they will report Q1, 2024 results on May 03, 2024 Reported Earnings • Mar 15
Full year 2023 earnings released: NT$2.81 loss per share (vs NT$2.82 loss in FY 2022) Full year 2023 results: NT$2.81 loss per share. Net loss: NT$338.0m (loss widened 3.1% from FY 2022). Ankündigung • Mar 02
Intech Biopharm Corporation, Annual General Meeting, May 24, 2024 Intech Biopharm Corporation, Annual General Meeting, May 24, 2024. Location: 1F., No.207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City 114, Taiwan(Xue Xue Institute) Taipei City Taiwan Agenda: To report Business Report of 2023; to report Audit Committees Review Report of 2023; to report the implementation of the 2023 Business Plan; to acknowledge adoption of the 2023 Business Report and Financial Statements; to acknowledge adoption of the proposal for 2023 Deficit Compensation Statement; to discuss and approve the lifting of non-competition restrictions for directors of the Company; and to consider other matters. New Risk • Dec 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.4% per year over the past 5 years. Revenue is less than US$1m (NT$25m revenue, or US$787k). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Oct 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.8% per year over the past 5 years. Revenue is less than US$1m (NT$20m revenue, or US$630k). Minor Risk Market cap is less than US$100m (NT$3.20b market cap, or US$99.2m). Reported Earnings • Aug 11
Second quarter 2023 earnings released: NT$0.62 loss per share (vs NT$0.73 loss in 2Q 2022) Second quarter 2023 results: NT$0.62 loss per share (improved from NT$0.73 loss in 2Q 2022). Net loss: NT$72.8m (loss narrowed 14% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Mar 31
Full year 2022 earnings released: NT$2.82 loss per share (vs NT$2.97 loss in FY 2021) Full year 2022 results: NT$2.82 loss per share. Net loss: NT$327.9m (loss widened 8.7% from FY 2021). Reported Earnings • Nov 16
Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021) Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021). Reported Earnings • Nov 13
Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021) Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021). Reported Earnings • Aug 15
Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.82 loss in 2Q 2021) Second quarter 2022 results: NT$0.73 loss per share. Net loss: NT$84.4m (loss widened 2.6% from 2Q 2021). Reported Earnings • May 16
First quarter 2022 earnings released: NT$0.60 loss per share (vs NT$0.68 loss in 1Q 2021) First quarter 2022 results: NT$0.60 loss per share. Net loss: NT$69.2m (loss widened 1.9% from 1Q 2021). Reported Earnings • Mar 30
Full year 2021 earnings released: NT$2.97 loss per share (vs NT$2.50 loss in FY 2020) Full year 2021 results: NT$2.97 loss per share (down from NT$2.50 loss in FY 2020). Net loss: NT$301.8m (loss widened 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 15
Third quarter 2021 earnings released: NT$0.71 loss per share (vs NT$0.65 loss in 3Q 2020) Third quarter 2021 results: Net loss: NT$71.7m (loss widened 9.4% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year. Reported Earnings • Aug 18
Second quarter 2021 earnings released: NT$0.82 loss per share (vs NT$0.59 loss in 2Q 2020) Second quarter 2021 results: Net loss: NT$82.3m (loss widened 38% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • May 17
First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.60 loss in 1Q 2020) First quarter 2021 results: Net loss: NT$67.9m (loss widened 13% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 26
Full year 2020 earnings released: NT$2.50 loss per share (vs NT$3.82 loss in FY 2019) Full year 2020 results: Net loss: NT$250.4m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Ankündigung • Mar 11
Intech Biopharm Corporation, Annual General Meeting, May 28, 2021 Intech Biopharm Corporation, Annual General Meeting, May 28, 2021. Is New 90 Day High Low • Dec 03
New 90-day high: NT$23.10 The company is up 13% from its price of NT$20.40 on 04 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.65 loss per share Third quarter 2020 results: Net loss: NT$65.6m (loss narrowed 19% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 26
New 90-day low: NT$20.05 The company is down 1.0% from its price of NT$20.20 on 28 July 2020. The Taiwanese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period. 